Which has better earnings and valuation, ZBH or PEN?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.19 $705.20M $4.11 23.00 Penumbra $1.40B 9.02 $177.69M $4.07 78.99

Is ZBH or PEN more profitable?

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Zimmer Biomet 9.48% 13.12% 7.23% Penumbra 10.67% 10.50% 8.17%

Does the media prefer ZBH or PEN?

In the previous week, Zimmer Biomet had 4 more articles in the media than Penumbra. MarketBeat recorded 6 mentions for Zimmer Biomet and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.53 beat Zimmer Biomet's score of 0.38 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BSX or ZBH?

In the previous week, Boston Scientific had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 12 mentions for Boston Scientific and 6 mentions for Zimmer Biomet. Boston Scientific's average media sentiment score of 0.42 beat Zimmer Biomet's score of 0.38 indicating that Boston Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Zimmer Biomet 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BDX or ZBH?

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 12 mentions for Becton, Dickinson and Company and 6 mentions for Zimmer Biomet. Becton, Dickinson and Company's average media sentiment score of 0.87 beat Zimmer Biomet's score of 0.38 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EW or ZBH?

In the previous week, Zimmer Biomet had 1 more articles in the media than Edwards Lifesciences. MarketBeat recorded 6 mentions for Zimmer Biomet and 5 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 0.75 beat Zimmer Biomet's score of 0.38 indicating that Edwards Lifesciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZBH or IDXX?

In the previous week, IDEXX Laboratories had 13 more articles in the media than Zimmer Biomet. MarketBeat recorded 19 mentions for IDEXX Laboratories and 6 mentions for Zimmer Biomet. IDEXX Laboratories' average media sentiment score of 1.42 beat Zimmer Biomet's score of 0.38 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zimmer Biomet (ZBH) Competitors

$94.90 +0.52 (+0.55%)

Closing price 03:59 PM Eastern

Extended Trading

$93.90 -1.00 (-1.06%)

As of 07:30 PM Eastern

Compare

ZBH vs. PEN, BSX, BDX, EW, and IDXX

Should you buy Zimmer Biomet stock or one of its competitors? Zimmer Biomet's main competitors and comparable companies include Penumbra (PEN), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and IDEXX Laboratories (IDXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zimmer Biomet presently has a consensus price target of $103.33, suggesting a potential upside of 9.33%. Penumbra has a consensus price target of $367.07, suggesting a potential upside of 14.18%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	1 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.23
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Zimmer Biomet has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.19	$705.20M	$4.11	23.00
Penumbra	$1.40B	9.02	$177.69M	$4.07	78.99

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Penumbra	10.67%	10.50%	8.17%

In the previous week, Zimmer Biomet had 4 more articles in the media than Penumbra. MarketBeat recorded 6 mentions for Zimmer Biomet and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.53 beat Zimmer Biomet's score of 0.38 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet and Penumbra tied by winning 8 of the 16 factors compared between the two stocks.

How does Zimmer Biomet compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Boston Scientific had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 12 mentions for Boston Scientific and 6 mentions for Zimmer Biomet. Boston Scientific's average media sentiment score of 0.42 beat Zimmer Biomet's score of 0.38 indicating that Boston Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zimmer Biomet	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Boston Scientific has higher revenue and earnings than Zimmer Biomet. Boston Scientific is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.19	$2.90B	$2.47	17.88
Zimmer Biomet	$8.23B	2.19	$705.20M	$4.11	23.00

Boston Scientific currently has a consensus target price of $68.23, suggesting a potential upside of 54.46%. Zimmer Biomet has a consensus target price of $103.33, suggesting a potential upside of 9.33%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	3 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.81
Zimmer Biomet	1 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.23

Boston Scientific has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Boston Scientific has a net margin of 17.50% compared to Zimmer Biomet's net margin of 9.48%. Boston Scientific's return on equity of 19.28% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.50%	19.28%	10.89%
Zimmer Biomet	9.48%	13.12%	7.23%

Summary

Boston Scientific beats Zimmer Biomet on 14 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Becton, Dickinson and Company presently has a consensus price target of $185.07, suggesting a potential downside of 4.52%. Zimmer Biomet has a consensus price target of $103.33, suggesting a potential upside of 9.33%. Given Zimmer Biomet's higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35
Zimmer Biomet	1 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.23

Zimmer Biomet has a net margin of 9.48% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	4.52%	14.79%	6.93%
Zimmer Biomet	9.48%	13.12%	7.23%

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 12 mentions for Becton, Dickinson and Company and 6 mentions for Zimmer Biomet. Becton, Dickinson and Company's average media sentiment score of 0.87 beat Zimmer Biomet's score of 0.38 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.2%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zimmer Biomet pays out 23.4% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	2.45	$1.68B	$3.32	58.38
Zimmer Biomet	$8.23B	2.19	$705.20M	$4.11	23.00

Becton, Dickinson and Company has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Summary

Becton, Dickinson and Company beats Zimmer Biomet on 10 of the 19 factors compared between the two stocks.

How does Zimmer Biomet compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Edwards Lifesciences has a net margin of 15.43% compared to Zimmer Biomet's net margin of 9.48%. Edwards Lifesciences' return on equity of 15.68% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	15.43%	15.68%	12.05%
Zimmer Biomet	9.48%	13.12%	7.23%

In the previous week, Zimmer Biomet had 1 more articles in the media than Edwards Lifesciences. MarketBeat recorded 6 mentions for Zimmer Biomet and 5 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 0.75 beat Zimmer Biomet's score of 0.38 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edwards Lifesciences currently has a consensus target price of $100.27, indicating a potential upside of 13.88%. Zimmer Biomet has a consensus target price of $103.33, indicating a potential upside of 9.33%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Edwards Lifesciences is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82
Zimmer Biomet	1 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.23

79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Edwards Lifesciences has higher earnings, but lower revenue than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	8.36	$1.07B	$1.74	50.60
Zimmer Biomet	$8.23B	2.19	$705.20M	$4.11	23.00

Edwards Lifesciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Summary

Edwards Lifesciences beats Zimmer Biomet on 12 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to IDEXX Laboratories?

Zimmer Biomet (NYSE:ZBH) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

In the previous week, IDEXX Laboratories had 13 more articles in the media than Zimmer Biomet. MarketBeat recorded 19 mentions for IDEXX Laboratories and 6 mentions for Zimmer Biomet. IDEXX Laboratories' average media sentiment score of 1.42 beat Zimmer Biomet's score of 0.38 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IDEXX Laboratories has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.19	$705.20M	$4.11	23.00
IDEXX Laboratories	$4.55B	9.47	$1.06B	$14.22	38.48

Zimmer Biomet has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Zimmer Biomet currently has a consensus price target of $103.33, indicating a potential upside of 9.33%. IDEXX Laboratories has a consensus price target of $747.00, indicating a potential upside of 36.52%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	1 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.23
IDEXX Laboratories	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

IDEXX Laboratories has a net margin of 25.03% compared to Zimmer Biomet's net margin of 9.48%. IDEXX Laboratories' return on equity of 71.96% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
IDEXX Laboratories	25.03%	71.96%	33.60%

Summary

IDEXX Laboratories beats Zimmer Biomet on 12 of the 15 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$18.00B	$5.73B	$7.44B	$23.17B
Dividend Yield	1.02%	1.73%	2.50%	3.69%
P/E Ratio	11.13	18.59	177.31	20.60
Price / Sales	2.20	63.47	567.95	21.29
Price / Cash	6.87	32.03	76.54	36.50
Price / Book	1.48	5.73	10.29	4.69
Net Income	$705.20M	$146.25M	$3.50B	$1.07B
7 Day Performance	6.58%	-2.67%	-5.37%	-0.83%
1 Month Performance	-2.05%	-4.22%	-8.55%	-2.63%
1 Year Performance	-5.02%	2.95%	0.43%	6.54%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	3.0813 of 5 stars	$94.90 +0.6%	$103.33 +8.9%	-5.0%	$18.00B	$8.23B	11.13	17,000
PEN Penumbra	2.0345 of 5 stars	$320.80 +0.4%	$367.07 +14.4%	+27.2%	$12.58B	$1.40B	78.82	4,700	Analyst Forecast
BSX Boston Scientific	4.885 of 5 stars	$43.78 +2.5%	$68.60 +56.7%	-54.8%	$61.93B	$20.07B	17.73	59,000	News Coverage Analyst Forecast
BDX Becton, Dickinson and Company	3.5498 of 5 stars	$188.35 +2.5%	$185.07 -1.7%	+3.8%	$50.63B	$21.84B	56.73	72,000
EW Edwards Lifesciences	3.5455 of 5 stars	$86.19 +1.1%	$100.27 +16.3%	+20.7%	$49.06B	$6.07B	49.53	16,000	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, BDX, EW, and IDXX

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, BDX, EW, and IDXX

How does Zimmer Biomet compare to Penumbra?

Do institutionals & insiders believe in ZBH or PEN?

Do analysts rate ZBH or PEN?

Which has more risk and volatility, ZBH or PEN?

Which has better earnings and valuation, ZBH or PEN?

Is ZBH or PEN more profitable?

Does the media prefer ZBH or PEN?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Do insiders & institutionals believe in BSX or ZBH?

Does the media prefer BSX or ZBH?

Which has higher valuation and earnings, BSX or ZBH?

Do analysts rate BSX or ZBH?

Which has more volatility and risk, BSX or ZBH?

Is BSX or ZBH more profitable?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Do analysts rate BDX or ZBH?

Is BDX or ZBH more profitable?

Does the media favor BDX or ZBH?

Do insiders and institutionals hold more shares of BDX or ZBH?

Is BDX or ZBH a better dividend stock?

Which has better valuation & earnings, BDX or ZBH?

Which has more risk and volatility, BDX or ZBH?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Is EW or ZBH more profitable?

Does the media prefer EW or ZBH?

Do analysts prefer EW or ZBH?

Do insiders and institutionals have more ownership in EW or ZBH?

Which has better valuation and earnings, EW or ZBH?

Which has more risk and volatility, EW or ZBH?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Does the media refer more to ZBH or IDXX?

Do insiders & institutionals believe in ZBH or IDXX?

Which has better valuation and earnings, ZBH or IDXX?

Which has more risk & volatility, ZBH or IDXX?

Do analysts prefer ZBH or IDXX?

Is ZBH or IDXX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools